Tag: Non-24 Disorder

All

Vanda Seeks New Markets for Hetlioz Amid Generic Competition

The pharmaceutical company continues to pursue FDA approval for jet lag and insomnia, as Hetlioz faces a 28% sales decline.

Vanda Highlights Q2 Efforts to Expand Hetlioz Amid Regulatory and Market Challenges
Vanda’s Hetlioz Faces Dipping Revenue and FDA Challenges in Q1 Report
Some States Extend HETLIOZ Coverage to Patients With Non-24 Who Are Not Totally Blind
The Lancet: Hetlioz, Taken Daily at Fixed Time, Promotes Master Body Clock Entrainment
What You Need to Know About Non-24
National Organization for Rare Disorders to Honor Hetlioz

All

In Q42014, Hetlioz Sales Increase 15% Compared to Q32014

“2014 was a transformational year for Vanda with the Hetlioz launch in the US for the treatment of Non-24-Hour Sleep-Wake Disorder. We are impressed with the continued growth of HETLIOZ and are fortunate to be able to...

Hetlioz US Sales Grow to $5.2 Million in First Full Quarter Since Launch
More Than 420 Prescriptions Written for Hetlioz
European Medicines Agency Accepts Hetlioz Marketing Authorization Application
Vanda Reports Net Loss of $26.5 Million Due in Part to Hetlioz Launch Expenses
Blind Adventurer Raises Awareness of Non-24 with Vanda Pharmaceuticals
FDA Approves Hetlioz for Non-24-Hour Disorder

Tag: Non-24 Disorder

All

Vanda Seeks New Markets for Hetlioz Amid Generic Competition

Vanda Highlights Q2 Efforts to Expand Hetlioz Amid Regulatory and Market Challenges

Vanda’s Hetlioz Faces Dipping Revenue and FDA Challenges in Q1 Report

Some States Extend HETLIOZ Coverage to Patients With Non-24 Who Are Not Totally Blind

The Lancet: Hetlioz, Taken Daily at Fixed Time, Promotes Master Body Clock Entrainment

What You Need to Know About Non-24

National Organization for Rare Disorders to Honor Hetlioz

All

In Q42014, Hetlioz Sales Increase 15% Compared to Q32014

Hetlioz US Sales Grow to $5.2 Million in First Full Quarter Since Launch

More Than 420 Prescriptions Written for Hetlioz

European Medicines Agency Accepts Hetlioz Marketing Authorization Application

Vanda Reports Net Loss of $26.5 Million Due in Part to Hetlioz Launch Expenses

Blind Adventurer Raises Awareness of Non-24 with Vanda Pharmaceuticals

FDA Approves Hetlioz for Non-24-Hour Disorder

All

Sorry, No Posts Found

Sorry, No Posts Found

Sleep Review

Our Parent Company

Key Resources

Helpful Links